{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Failure was defined as clinically significant bacteraemia occurring in the period of neutropenia and an intervention with a systemic antibacterial becoming necessary.\n\nWith this being a discontinuation criteria and the outcome being measured at end of treatment, only one episode is taken into account for each participant.","groups":[{"description":"moxifloxacin 400 mg tablets once daily","id":"OG000","title":"Moxifloxacin"},{"description":"identical appearing placebo","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"intention to treat (ITT)","reportingStatus":"POSTED","timeFrame":"end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)","title":"Incidence of Clinically Significant Bacteremia","type":"PRIMARY","unitOfMeasure":"participants"}